Assessing the Therapeutic Potential of Lab-Made Hepatocytes

Rezvani, M. Grimm, A. Willenbring, H.

Hepatology. 2016 Mar 25. doi: 10.1002/hep.28569

Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/27651415

Kan, H. Imamura, M. Uchida, T. Hiraga, N. Hayes, C. N. Tsuge, M. Abe, H. Aikata, H. Makokha, G. N. Chowdhury, S. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Infect Dis. 2016 Sep 20. pii: jiw437.

Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/27515132

Tanaka, T. Okuyama-Dobashi, K. Murakami, S. Chen, W. Okamoto, T. Ueda, K. Hosoya, T. Matsuura, Y. Ryo, A. Tanaka, Y. Hagiwara, M. Moriishi, K.

Antiviral Res. 2016 Aug 8. pii: S0166-3542(16)30357-6.

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/27272497

DebRoy, S.  Hiraga, N. Imamura, M. Hayes, C. N. Akamatsu, S. Canini, L. Perelson, A. S. Pohl, R. T. Persiani, S. Uprichard, S. L. Tateno, C. Dahari, H. Chayama, K.

J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.

新規核酸アナログ4′-C-cyano-2′-deoxyadenosine, 4′-C-cyano-2′-deoxyguanosineは薬剤耐性B型肝炎ウイルス変異種に対して有効である(短報)

林　佐奈衣、高松悠樹、前田賢次、村上周子，尾曲克已、松居剛志、五十川正記、渡邊網正、狩野吉康、向後悟、濱屋裕明、田中靖人

肝臓 2016; 57(6):299-301

Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/27087417

Toyoda, Y. Takada, T. Suzuki, H.

Sci Rep. 2016 Apr 18;6:24586. doi: 10.1038/srep24586.

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26943168

Tsuge, M. Hiraga, N. Uchida, T. Kan, H. Miyaki, E. Masaki, K. Ono, A. Nakahara, T. Abe-Chayama, H. Zhang, Y. Naswa, M. G. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Chayama, K.

J Gastroenterol. 2016 Mar 4.

Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26731332

Sasaki, R. Kanda, T. Nakamura, M. Nakamoto, S. Haga, Y. Wu, S. Shirasawa, H. Yokosuka, O.

PLoS One. 2016 Jan 5;11(1):e0146314. doi: 10.1371/journal.pone.0146314. eCollection 2016.

A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26378168

Kaneko, M. Watashi, K. Kamisuki, S. Matsunaga, H. Iwamoto, M. Kawai, F. Ohashi, H. Tsukuda, S. Shimura, S. Suzuki, R. Aizaki, H. Sugiyama, M. Park, S. Y. Ito, T. Ohtani, N. Sugawara, F. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15.

動物モデルを用いた発癌研究

森屋恭爾、三好秀征、小池和彦

新ウイルス性肝炎学 2015 page74-78

ヒト肝細胞キメラマウスを用いたin vivoおよびin vitro HBV感染モデル

石田雄二、横道博、加国雅和、立野知世

新ウイルス性肝炎学 2015 page386-391

HepDART 2015でのPXBマウスおよびPXB-cells関連研究発表のご案内

2015年 12月6日(日)～12月10日(木)にGrand Wailea(Maui, Hawaii)にて開催されましたHepDART 2015

にてPXBマウスおよびPXB-cells関連研究発表がありましたので、ご案内申し上げます。

In Vitro and in Vivo Assessments of Drug-induced Hepatotoxicity and Drug Metabolism in Humans (In Japanese)(ヒトにおける医薬品の肝毒性及び代謝物のin vtro, in vivo予測評価系の構築に関する研究）

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26521876

Sanoh, S.

Yakugaku Zasshi. 2015;135(11):1273-9. doi: 10.1248/yakushi.15-00200.

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26505121

Yamamoto, N. Sato, Y. Munakata, T. Kakuni, M. Tateno, C. Sanada, T. Hirata, Y. Murakami, S.  Tanaka, Y. Chayama, K. Hatakeyama, H. Hyodo, M. Harashima, H. Kohara, M.

J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00713-8. doi: 10.1016/j.jhep.2015.10.014.

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26569595

Uchida, T. Hiraga, N. mamura, M. Yoshimi, S. Kan, H. Miyaki, E. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Ellis, J. D. Chayama, K.

Virus Res. 2015 Nov 10. pii: S0168-1702(15)30117-9. doi: 10.1016/j.virusres.2015.11.010.

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26562322

Kan, H. Hiraga, N. Imamura, M. Hayes, C. N. Uchida, T. Miyaki, E. Tsuge, M. Abe, H. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3009.

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26515673

Murakami, E. Tsuge, M. Hiraga,  N.Kan, H. Uchida, T. Masaki, K. Nakahara, T. Ono, A. Miki, D. Kawaoka, T. Abe, H.Imamura, M. Aikata, H. Ochi, H. Hayes, C. N. Akita, T. Tanaka, J. Chayama, K.

J Infect. 2015 Oct 26. pii: S0163-4453(15)00339-4. doi: 10.1016/j.jinf.2015.09.038.

Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26536627

Tateno, C. Kawase, Y. Tobita, Y. Hamamura, S. Ohshita, H. Yokomichi, H. Sanada, H. Kakuni, M. Shiota, A. Kojima, Y. Ishida, Y. Shitara, H. Wada, N. A. Tateishi, H. Sudoh, M. Nagatsuka, S. Jishage, K. Kohara, M.

PLoS One. 2015 Nov 4;10(11):e0142145. doi: 10.1371/journal.pone.0142145. eCollection 2015.

A novel reporter system to monitor early stages of the HBV life cycle

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26310603

Nishitsuji, H. Ujino, S. Shimizu, Y. Harada, K. Zhang, J. Sugiyama, M. Mizokami, M. Shimotohno, K.

Cancer Sci. 2015 Aug 27. doi: 10.1111/cas.12799.

Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound

• Pub Med URL http://www.ncbi.nlm.nih.gov/pubmed/26444900

Kamimura, H. Ito, S.

Xenobiotica. 2015 Oct 7:1-13.